After-Hours Stock Movers:
Cardiff Oncology, Inc. (Nasdaq: CRDF) 16.6% LOWER; announced new data from its lead clinical program evaluating onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). A subset of these data will be featured in a poster presented by Dr. Heinz-Josef Lenz, principal investigator, USC Norris Comprehensive Cancer Center, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCOGI) on Saturday, January 22, 2022.
SoFi Technologies, Inc. (NASDAQ: SOFI) 10.8% HIGHER; The Office of the Comptroller of the Currency (OCC) today conditionally approved applications from Social Finance Inc. (SoFi) (NASDAQ: SOFI) to create SoFi Bank, National Association (SoFi Bank, N.A.), as a full service national bank headquartered in Cottonwood Heights, Utah. As part of the transaction, SoFi Bank, N.A. will acquire Golden Pacific Bank, National Association, a national bank insured by the Federal Deposit Insurance Corporation.
ADS (NYSE: ADS) 5.9% LOWER; BJ's Wholesale Club (NYSE: BJ) Moving Co-Branded Credit Cards to Capital One (NYSE: COF) in Blow to ADS (NYSE: ADS) - WSJ
Concentrix Corporation (NASDAQ: CNXC) 5% HIGHER; reported Q4 EPS of $2.99, $0.28 better than the analyst estimate of $2.71. Revenue for the quarter came in at $1.47 billion versus the consensus estimate of $1.46 billion. Concentrix Corporation sees FY2022 revenue of $6.45-6.6 billion, versus the consensus of $6.16 billion.
TEGNA (NYSE: TGNA) 4.3% HIGHER; Standard General, Apollo Global (NYSE: APO) Close in on $9B Deal for TEGNA (NYSE: TGNA).
Revance Therapeutics, Inc. (Nasdaq: RVNC) 4.2% HIGHER; received the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for DaxibotulinumtoxinA for Injection for glabellar lines. The Type A meeting was held on December 15, 2021.
Venus Concept Inc. (NASDAQ: VERO 2.3% HIGHER; received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Venus BlissMAX device (BlissMAX) in the United States.